Currentblue cross blue shield - louisianaPolicy AHS - G2121

Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Defines coverage for fecal and serologic laboratory tests used to differentiate IBD from non-inflammatory GI disease and to monitor IBD, and lists tests that do and do not meet coverage criteria. Includes terminology, scientific background, and guideline citations.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyLaboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Policy CodePolicy AHS - G2121

Change TypeAdded/combined coverage criteria; coding additions; clarifications

Effective DateMar 15, 2026

Next Review Date

Key ActionVerify member benefits prior to ordering and preferentially order fecal calprotectin (only fecal calprotectin will be approved if ordered with fecal lactoferrin).

SourceLink

POLICY UPDATE CHANGES

Combined contents of G2061-Fecal Calprotectin Testing in Adults with this policy, adding new CC1 and CC2 indicating fecal calprotectin or fecal lactoferrin testing meets coverage for differential diagnosis (IBS vs IBD) and for monitoring IBD.

Added CPT codes 83630, 83993 and code 0598U.

Former CC2 became CC4 and edited for clarity: multianalyte serum biomarker panels (with or without algorithmic analysis) designed to distinguish IBD from non-IBD or to diagnose/monitor IBD DO NOT MEET COVERAGE CRITERIA.

Removed CC3 (genetic testing for IBD) because genetic testing is managed by separate germline policy M2145.

Client requested variance: removal of PredictSURE IBD from CC2.

1Preferred biomarker (fecal calprotectin)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Scope: This policy (AHS - G2121) addresses laboratory testing for diagnosis and monitoring of inflammatory bowel disease (IBD) and defines which fecal and serologic tests meet or do not meet coverage criteria. Status: CURRENT. Subject: Laboratory testing for diagnosis and monitoring of IBD (Crohn's disease and ulcerative colitis). Effective / last review date: 03/15/2026 (Current Effective Date).

Primary covered indications: Fecal calprotectin or fecal lactoferrin testing MEETS COVERAGE CRITERIA for (1) the differential diagnosis between non-inflammatory GI disease (e.g., IBS) and inflammatory disease (e.g., IBD) and (2) to monitor individuals with IBD (e.g., assess response to therapy or relapse).

Primary not-covered categories: Serologic markers (examples: pANCA, ASCA, OmpC, CBir1, antiglycan antibodies, PKM2, etc.) and multianalyte serum biomarker panels (with or without algorithmic analysis; examples: ibs-smart™, IBSchek®, Prometheus®) DO NOT MEET COVERAGE CRITERIA for diagnosis or monitoring of IBD.

Policy notes & coding: Fecal calprotectin is preferred when both fecal calprotectin and fecal lactoferrin are ordered concurrently only fecal calprotectin will be approved; applicable codes listed in policy include 83993 (calprotectin, fecal) and 83630 (lactoferrin, fecal) (see listed CPT/HCPCS references).

Key thresholds and quick facts

Common FC cutoffs50 µg/g (most manufacturers); 150 µg/g recommended in young patients; ≤100 µg/g considered normalized

Repeat testing window50–150 µg/g should be repeated 2–3 weeks later

Primary covered indications (count)2 (differential diagnosis IBS vs IBD; monitoring IBD)

Primary not-covered categoryMultianalyte serum biomarker panels (e.g., ibs-smart™, IBSchek®, Prometheus®) — not covered

Concurrent fecal tests noteFecal calprotectin is preferred; if both calprotectin and lactoferrin ordered simultaneously, only fecal calprotectin will be approved

Medical Necessity / Coverage Criteria

Covered when ALL of the following are met

Covered when ALL of the following are met:

ALL of the following

ONE OF
- Fecal calprotectin testing
- Fecal lactoferrin testing
Testing is being used for the differential diagnosis between non-inflammatory gastrointestinal disease (e.g., irritable bowel syndrome) and inflammatory gastrointestinal disease (e.g., inflammatory bowel disease)
Or testing is being used to monitor individuals with known inflammatory bowel disease (e.g., to assess response to therapy or detect relapse)

Provider Actions / Billing & Documentation

Documentation Required

Benefit verification

Verify the member's benefits and coverage for fecal biomarker testing (fecal calprotectin, fecal lactoferrin) and related laboratory tests prior to ordering. Coverage is benefit-dependent and may vary by product, Medicare/Medicaid status, and state.

Confirm medical necessity and applicability of policy criteria for the specific member.
Obtain prior authorization when required by the member's plan or government payer rules.

Billing Rule

Concurrent fecal tests

If both fecal calprotectin and fecal lactoferrin are ordered for the same clinical encounter, only fecal calprotectin will be approved. Order a single fecal biomarker when both are requested to avoid claim denials or edits.

When both tests are submitted, reimbursement will be limited to the fecal calprotectin test.

Coding

Applicable CPT/HCPCS Procedure Codes (listed in policy)CPT

0164U	Gastroenterology (IBS), immunoassay for anti-CdtB and anti-vinculin antibodies, plasma, algorithm, qualitative. Proprietary test: ibs-smart™.
0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ELISA). Proprietary test: IBSchek®.
0598U	Gastroenterology (IBS), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report elevated/normal. Proprietary: inFoods® IBS Test.
82397	Chemiluminescent assay.
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method.
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified.
83630	Lactoferrin, fecal; qualitative.
83993	Calprotectin, fecal.
86021	Antibody identification; leukocyte antibodies.
86036	Antineutrophil cytoplasmic antibody (ANCA); screen, each antibody.

1–10 of 15

1/2

Applicable CPT/HCPCS Procedure Codes (listed in policy)CPT

No codes listed

Added codes per revision historymixed

83630	Added CPT code (Lactoferrin, fecal; qualitative).
83993	Added CPT code (Calprotectin, fecal).
0598U	Added PLA/other code (Gastroenterology (IBS), IgG antibodies to 18 food items by microarray-based immunoassay).

Examples of proprietary/diagnostic tests named in policy (not covered)mixedNot Covered

ibs-smart	Proprietary test (example of multianalyte panel) — listed as not meeting coverage criteria.
IBScheck	Proprietary test — listed as not meeting coverage criteria.
Prometheus	Prometheus® testing — listed as not meeting coverage criteria.

Examples of proprietary/diagnostic tests named in policy (not covered)mixedNot Covered

No codes listed

Background & Evidence Summary

Background: Crohn's disease and ulcerative colitis are the two major IBD disorders with distinct pathologic and clinical features—ulcerative colitis causes continuous mucosal inflammation limited to the colon beginning at the rectum, whereas Crohn's disease causes patchy, transmural inflammation that can produce skip lesions, fistulae, fibrosis, and strictures.

Fecal biomarkers: Fecal calprotectin (and fecal lactoferrin) are sensitive markers of intestinal inflammation that correlate with endoscopic indices; multiple meta-analyses report high sensitivity and specificity (>90% in some analyses using a ~50 µg/g cutoff) for distinguishing IBD from IBS and supportive data for monitoring disease activity and predicting relapse or postoperative recurrence.

Serologic markers and panels: Although many serologic antibodies (e.g., pANCA, ASCA, OmpC, CBir1, antiglycan antibodies, PKM2) and combined serologic/genetic/inflammatory panels have been studied, the policy finds their clinical validity and utility for routine diagnosis or monitoring of IBD to be uncertain or insufficient; multianalyte serum biomarker panels (with or without algorithmic analysis, e.g., ibs-smart™, IBSchek®, Prometheus®) do not meet coverage criteria.

Measure	Value
Meta-analysis sensitivity/specificity (Waugh et al.)	Pooled sensitivity ~93% and specificity ~94% for FC at cutoff 50 µg/g
Post-induction fecal calprotectin cutoff	139 µg/g → sensitivity 72%, specificity 80% to predict clinically active disease after 1 year (Molander et al.)
Post-op Crohn's recurrence optimal cutoff	150 µg/g → sensitivity 70%, specificity 69% (Tham et al. meta-analysis)
FC predictive performance (>160 µg/g)	FC >160 µg/g: sensitivity 91.7%, specificity 82.9% for predicting relapse in infliximab-induced remission
FC post-op recurrence (>100 µg/g)	FC >100 µg/g indicates endoscopic recurrence post-ileocolic resection with sensitivity ~89%
Policy literature update note	Background, guidelines, and evidence references updated; combined G2061 into this policy and coverage criteria revised effective 03/15/2026 (revision history)

Clinical Guidance Summaries

Recommendations and statements from professional societies regarding laboratory testing in IBD patients:

AGA: In patients with UC, no recommendation for biomarker-based monitoring strategy over endoscopy to improve long-term outcomes; suggests endoscopic assessment rather than empiric treatment adjustment when biomarkers are discordant.

Definitions / Terms

Fecal calprotectin: A fecal biomarker of intestinal inflammation, preferred for distinguishing IBD from IBS and for monitoring disease activity.

Fecal lactoferrin: A fecal biomarker of inflammation; covered in the same situations as calprotectin but calprotectin is preferred when both are ordered.

Serologic markers: Blood antibodies (e.g., ASCA, pANCA, OmpC, CBir1, ACCA, ALCA, AMCA, PKM2) investigated for IBD diagnosis/monitoring; policy deems them not meeting coverage criteria for routine workup/monitoring.

Multianalyte serum biomarker panels: Commercial panels combining serologic, genetic, and inflammatory markers (e.g., Prometheus®) designed to distinguish IBD from non-IBD or monitor IBD; not covered.

FC: Abbreviation for fecal calprotectin, a fecal biomarker indicative of intestinal inflammation.

pANCA / ASCA: Perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies—serologic markers with limited sensitivity/specificity for IBD classification and not recommended for routine use.

LDT: Laboratory-developed test; regulated by CMS under CLIA as high-complexity tests and not FDA-approved/cleared, though FDA clearance is not required for clinical use.

Note 1: Fecal calprotectin is the preferred biomarker. If fecal calprotectin and fecal lactoferrin are ordered at the same time, only fecal calprotectin will be approved.

Revision History

2026-03-15literature_updateLatest

Reviewed and updated background, guidelines, and evidence-based references; combined contents of G2061 (Fecal Calprotectin Testing in Adults) into this policy resulting in addition of new CC1 and CC2: CC1—Fecal calprotectin or fecal lactoferrin testing meets coverage for differential diagnosis (IBS vs IBD); CC2—meets coverage for monitoring individuals with IBD (assess response to therapy or relapse). Former CC2 edited and renumbered (multianalyte serum biomarker panels do not meet coverage). New Note 1 preferring fecal calprotectin and stating that if both fecal calprotectin and fecal lactoferrin are ordered concurrently only fecal calprotectin will be approved. Detailed change: Combined contents of G2061-Fecal Calprotectin Testing in Adults with this policy, adding new CC1 and CC2 indicating fecal calprotectin or fecal lactoferrin testing meets coverage for differential diagnosis (IBS vs IBD) and for monitoring IBD.

2025-10-01coding_update

Added CPT/HCPCS codes to policy: CPT codes 83630 and 83993 and code 0598U were added effective 10/01/2025. Detailed change: Added CPT codes 83630, 83993 and code 0598U.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyLaboratory Testing for the Diagnosis of Inflammatory Bowel Disease

Policy CodePolicy AHS - G2121

Change TypeAdded/combined coverage criteria; coding additions; clarifications

Effective DateMar 15, 2026

Next Review Date

Key ActionVerify member benefits prior to ordering and preferentially order fecal calprotectin (only fecal calprotectin will be approved if ordered with fecal lactoferrin).

SourceLink

On This Page

Not covered / Does not meet coverage criteria

Not covered / Does not meet coverage criteria:

ALL of the following

ONE OF
- Fecal calprotectin testing for indications other than the differential diagnosis between IBS and IBD or for monitoring individuals with IBD
- Fecal lactoferrin testing for indications other than the differential diagnosis between IBS and IBD or for monitoring individuals with IBD
The following serologic markers for the workup and monitoring of individuals with inflammatory bowel disease do NOT meet coverage criteria:
Examples of serologic markers
- Anti-neutrophil cytoplasmic antibody (ANCA) / perinuclear ANCA (pANCA)
- Anti-Saccharomyces cerevisiae antibody (ASCA)
- Antibody to Escherichia coli outer membrane porin C (OmpC)
- Anti-CBir1 flagellin antibody
- Antibody to Pseudomonas fluorescens–associated sequence I2 (anti-I2)
- Anti-chitobioside (ACCA), anti-laminaribioside (ALCA), or anti-mannobioside (AMCA) antibodies
- Pyruvate kinase M2 (PKM2)
The use of multianalyte serum biomarker panels (with or without algorithmic analysis) that are designed to distinguish between IBD and non-IBD or that are designed to diagnose or monitor IBD (e.g., ibs-smart™, IBSchek®, Prometheus® testing) DOES NOT MEET COVERAGE CRITERIA.

ALL of the following

Rationale: These tests lack sufficient published scientific literature confirming that they are required and beneficial for diagnosis and treatment of an individual's illness.

Policy note on concurrent testing

Policy note on concurrent testing:

ALL of the following

Fecal calprotectin is the preferred biomarker.
If fecal calprotectin and fecal lactoferrin are ordered at the same time, only fecal calprotectin will be approved.

ALL of the following

Operational note: When both tests are submitted concurrently, authorization/coverage adjudication will be limited to fecal calprotectin; fecal lactoferrin claims submitted alongside an approved fecal calprotectin may be denied or returned for correction.

Documentation Required

Use of serologic/panel tests

Serologic markers and multianalyte serum biomarker panels (including laboratory-developed panels and commercial panels such as Prometheus®, ibs-smart™, IBSchek®, and similar tests) are NOT covered for the diagnosis or routine monitoring of IBD. Do not use these tests as substitutes for covered fecal biomarkers or standard clinical evaluation.

Serologic markers (e.g., ANCA/pANCA, ASCA, anti-CBir1, OmpC, I2, anti-LFS, PKM2) are not covered for diagnosis/monitoring of IBD.
Multianalyte panels with or without algorithmic interpretation are not covered for diagnosis/monitoring of IBD.

Documentation Required

Use biomarkers with clinical correlation

When ordering and reporting fecal biomarkers, document how the test result correlates with the individual's clinical presentation, symptoms, and other objective assessments (e.g., endoscopy, imaging, histology, inflammatory markers). Correlation with clinical findings is required to support medical necessity for testing and ongoing management decisions.

Include relevant symptom history, physical findings, and recent endoscopic or imaging results in the medical record.
Document how the test result will affect clinical management (e.g., guide therapy change, avoid invasive testing).

Prior Authorization

Adhere to government payer determinations

Follow applicable government payer determinations (LCDs, NCDs, and state Medicaid policies). Government payer policies take precedence for Medicare and Medicaid beneficiaries.

Check Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs) for Medicare beneficiaries.
Adhere to state Medicaid coverage rules where applicable; when a conflict exists, follow the government payer determination.

Billing Rule

Report appropriate CPT/HCPCS

Report the appropriate CPT/HCPCS codes when submitting claims for fecal calprotectin and related fecal biomarker tests. Use the codes below as a reference; examples: CPT 83993 commonly maps to fecal calprotectin and CPT 83630 commonly maps to fecal lactoferrin. This list is for reference and may not be exhaustive — submitters are responsible for accurate coding based on the lab's reportable analyte and method.

Examples of procedure-code mappings: 83993 — Fecal calprotectin (example mapping); 83630 — Fecal lactoferrin (example mapping).
Verify the performing laboratory's CPT/HCPCS code assignment and submit the code(s) shown on the laboratory report.
When both fecal calprotectin (83993) and fecal lactoferrin (83630) are submitted for the same encounter, coverage will be limited to fecal calprotectin per policy Note 1.

Documentation Required

Use fecal calprotectin preferentially

Fecal calprotectin is the preferred fecal biomarker for differential diagnosis and monitoring of IBD. When both fecal calprotectin and fecal lactoferrin are ordered simultaneously, limit testing to a single approved fecal biomarker (fecal calprotectin) to comply with coverage rules.

Refer to Note 1 in the policy: fecal calprotectin is preferred and will be approved over fecal lactoferrin when both are ordered.

Billing Rule

Coding additions

Coding additions relevant to this policy revision: CPT codes 83630 and 83993 and the analyte-specific code 0598U were added effective 2025-10-01. Use the effective dates when reporting and adjudicating claims.

Effective 2025-10-01: added CPT 83630 (fecal lactoferrin) and CPT 83993 (fecal calprotectin) to the code set for this policy.
Effective 2025-10-01: added analyte-specific code 0598U (as applicable) per the revision history.
Use these additions as reference; confirm code applicability with the performing laboratory and payer billing guides.

FDA-cleared/approved fecal calprotectin assays

Devices approved/cleared by FDA and intended uses:

PhiCal (Genova Diagnostics) quantitative ELISA cleared March 2006: indicated to aid diagnosis of IBD and differentiation from IBS; to be used with other diagnostic testing and clinical considerations.

CalPrest (Eurospital) cleared January 2014; CalPrest NG cleared November 2016: described as identical to PhiCal with minor label/dynamic range differences.

QUANTA Flash Calprotectin and Fecal Extraction Device approved October 16, 2018: chemiluminescent immunoassay for quantitative determination of fecal calprotectin; aid in diagnosis of IBD and differentiation from IBS.

DiaSorin LIAISON Calprotectin assay approved/cleared December 26, 2018: quantitative measurement of fecal calprotectin on LIAISON XL Analyzer; aid in diagnosis of IBD and differentiation from IBS.

Buhlmann FCAL Turbo and CALEX Cap (BÜHLMANN fCAL turbo) FDA approval September 24, 2019: automated quantitative fecal calprotectin assay with extraction device.

Rapid fecal calprotectin point-of-care tests (e.g., CalproSmart) available internationally but not FDA-approved for U.S. use.

Testing utility statements / limitations

Statements about sensitivity, specificity, and limitations of biomarkers:

Fecal calprotectin and lactoferrin are sensitive markers of disease activity and correlate with endoscopic indices; levels >100 μg/g indicate endoscopic recurrence post-ileocolic resection with sensitivity ~89%; in infliximab-induced remission, FC >160 μg/g had sensitivity 91.7% and specificity 82.9% to predict relapse.

Normalization of biomarkers may occur despite active mucosal inflammation; biomarkers should not exclusively serve as endpoint for treatment.

pANCA and ASCA have limited sensitivity/specificity and are not recommended for routine classification or prognosis; serologic markers have modest yield.

Endoscopy remains gold standard for diagnosis and responsiveness; fecal calprotectin validity = good, responsiveness = good, signal-to-noise = moderate (risk of false positives), practicality = high.

2026-03-15coverage_revisionLatest

Former CC2 became CC4 and was edited for clarity to state that multianalyte serum biomarker panels (with or without algorithmic analysis) designed to distinguish IBD from non-IBD or to diagnose/monitor IBD (examples: ibs-smart™, IBSchek®, Prometheus®) DO NOT MEET COVERAGE CRITERIA. Detailed change: Former CC2 became CC4 and edited for clarity: multianalyte serum biomarker panels (with or without algorithmic analysis) designed to distinguish IBD from non-IBD or to diagnose/monitor IBD DO NOT MEET COVERAGE CRITERIA.